Kad­mon shares jump on lim­it­ed IPF da­ta; Cel­lec­tis grant­ed two US patents for edit­ing T cells with CRISPR

→ Kad­mon shares $KDMN spiked on some Phase II da­ta they’re tout­ing on on a ROCK2 in­hibitor for id­io­path­ic pul­monary fi­bro­sis. It’s a small study and fair­ly hard to read with­out any p val­ues, but the biotech point­ed to a me­di­an de­cline in forced vi­tal ca­pac­i­ty of 48 mL at week 24, com­pared to a me­di­an de­cline of 175 mL in pa­tients treat­ed with best sup­port­ive care.

→ Fol­low­ing a Eu­ro­pean patent, Cel­lec­tis $CLLS has been grant­ed two US patents to bol­ster busi­ness po­ten­tial for its CAR-T treat­ments. The patents were is­sued for “the in­ven­tion of cer­tain us­es of RNA-guid­ed en­donu­cle­as­es” — think CRISPR/Cas9 — for the ge­net­ic en­gi­neer­ing of T cells which are then used to fight can­cer. The French biotech in­tends to make these patents avail­able for li­cens­ing to com­pa­nies want­i­ng to use CRISPR tech in T cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER